№ 3/2023

Volume 16, number 3

 

 

 

 

 

 

REVIEWS

Perspectives for the Use of Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in the Treatment of Multiple Myeloma

SV Semochkin

PDF

pdficon

Classical Hodgkin Lymphoma: Tumor Structure and Prognostic Value of the Immune Microenvironment

AA Gusak, KV Lepik, LV Fedorova, VV Markelov, VV Baykov

PDF

pdficon

The Role of Leukocytes in the Formation of Neutrophil Extracellular Traps and Thrombosis in Ph-Negative Myeloproliferative Neoplasms: A Literature Review

BT Dzhumabaeva

PDF

pdficon

EXPERIMENTAL STUDIES

Classic and Activating Chimeric Antigen Receptors PD-1 as an Element of Multi-Target Approach to the Treatment of Hematological and Solid Neoplasms

KA Levchuk, AA Goldaeva, EA Stolyarova, PA Mateikovich, AKh Valiullina, ER Bulatov, AV Petukhov, AA Daks, NA Barlev, EV Baidyuk, YaG Toropova

PDF

pdficon

BONE MARROW TRANSPLANTATION

Nivo-BeGEV as Preparation for Autologous Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Classical Hodgkin Lymphoma: Results of a Multi-Center Prospective Clinical Study

YaK Mangasarova, TN Moiseeva, OV Margolin, LG Gorenkova, ES Nesterova, FE Babaeva, MO Bagova, EA Fastova, RR Abdurashidova, LS Al-Radi, EI Dorokhina, EM Volodicheva, VA Lapin, OS Samoilova, SK Kravchenko, AU Magomedova, EE Zvonkov

PDF

pdficon

Efficacy of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Patients Aged over 60 Years

II Kostroma, VA Yudina, RR Sabitova, ES Stepchenkova, ZhV Chubukina, SS Bessmeltsev, SV Sidorkevich, SV Gritsaev

PDF

pdficon

LYMPHOID TUMORS

Expression of the WNT Family Genes in Multiple Myeloma Patients with Different Chemotherapy Response

NI Enukashvili, LA Belik, II Kostroma, NYu Semenova, VA Balashova, DV Baram, SV Gritsaev, SS Bessmeltsev, SV Sidorkevich, IS Martynkevich

PDF

pdficon

Multiple Myeloma Complicated by Bone Plasmacytomas: Pathogenesis, Clinical Features, Treatment Approaches (A Literature Review)

EA Mamaeva, MV Solov’eva, LP Mendeleeva

PDF

pdficon

MYELOID TUMORS

Treatment Outcomes with Asciminib, the First Allosteric BCR::ABL1 Tyrosine Kinase Inhibitor, in Chronic Myeloid Leukemia Patients with Multiple Resistance to Prior Therapy

AG Turkina, EA Kuzmina

PDF

pdficon

ANEMIAS

Long-Term Outcomes of Immunosuppressive Therapy for Aplastic Anemia: A Single-Center Experience

ER Shilova, NA Romanenko, DA Chebykina, TV Glazanova, MN Zenina, IE Pavlova, SS Bessmeltsev

PDF

pdficon

COMPLICATIONS OF CHEMOTHERAPY

New Approaches to Cardiovascular Toxicity Assessment in Patients with Hematological Malignancies: A Literature Review

OE Danilova, GR Gimatdinova, IL Davydkin, OV Tereshina, VD Sabanova, GI Davydkin

PDF

pdficon

NEW TECHNOLOGIES

Mutation Profile of Normal and Tumor Cells in a Patient with Multiple Myeloma: A Case Report

AS Zhuk, II Kostroma, EI Stepchenkova, DV Kachkin, OB Belopolskaya, IV Zotova, AD Garifullin, SV Voloshin, SV Gritsaev, AYu Aksenova

PDF

pdficon

FROM THE EDITORS

From the Editors

PDF

pdficon